Investors and market participants can look forward to the unveiling of DexCom (NASDAQ: DXCM) third quarter financial results on Thursday 24th October 2024. This important update will be made available after market close.
In accordance with the forecasts of financial specialists on Wall Street, the company is primed to announce an anticipated $0.43 profit per share for the quarter. Additionally, the company is projected to reveal a total revenue of $990.98 million for this particular period.
Wall Street analysts have shared their forecasts for the company's annual performance, predicting a total revenue of $4.01 billion. Additionally, they expect the company to post profit of $1.7 per share for the fiscal year.
The earnings report for the corresponding quarter in the previous year showcased a per-share income of $0.5. This considerable sum was attributed to the company's total revenue, which reached an impressive $975 million during that specific quarter.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.43 | +26.5% | 1.00 B | +15.2% |
| Q1 2024 | $0.32 | +88.2% | 921.00 M | +24.2% |
| Q4 2023 | $0.50 | +47.1% | 1.03 B | +26.9% |
| Q3 2023 | $0.50 | +78.6% | 975.00 M | +26.7% |
| Q2 2023 | $0.34 | +100.0% | 871.30 M | +25.9% |
| *Growth on year-over-year basis | ||||
The business has scheduled a conference call on 24th October 2024 at 04:30 PM eastern time to discuss Q3 financial results.
Throughout Tuesday's trading, DexCom (DXCM) shares fluctuated between $71.84 and $73.12, with a trading volume of 2.78 million shares. The stock ended the regular trading session at $73.08, demonstrating a gain of 0.65 percent.
